Phaseline

Companies › Hefei Xinzhu Biological Technology

Hefei Xinzhu Biological Technology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
N-3C01–Phase 1Advanced Malignant Solid TumorsAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07639450N-3C01Phase 1Advanced Malignant Solid TumorsOncologyAug 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.